Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data i...

Descripción completa

Detalles Bibliográficos
Autores principales: Verheijen, Remy B., Yu, Huixin, Schellens, Jan H.M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D.R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656880/
https://www.ncbi.nlm.nih.gov/pubmed/28699160
http://dx.doi.org/10.1002/cpt.787
Descripción
Sumario:Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

Ejemplares similares